JAGUAR HEALTH, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
JAGUAR HEALTH, INC. (JAGX) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 10.67 million shares for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2023-08-14
- 2023-06-30: Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month 10.67M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|
| 2023-06-30 | 10.67M shares 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |